Reductive TCA Cycle Catalyzed by Wild-Type IDH2 Promotes Acute Myeloid Leukemia and Is a Metabolic Vulnerability for Potential Targeted Therapy

The role of wild-type isocitrate dehydrogenase-2 (IDH2) in AML cell survival and proliferation was tested using genetic knockdown and pharmacological inhibition in AML cells and animal models.